Breaking the aggregation of the monoclonal antibody bevacizumab (Avastin®) by dexamethasone phosphate: Insights from molecular modelling and asymmetrical flow field-flow fractionation

Pharmaceutical Research

Volumn 30, Issue 4, 2013, Pages 1176-1187

  Veurink, Marieke ^a   Westermaier, Yvonne ^a,c   Gurny, Robert ^a   Scapozza, Leonardo ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b Department of Pharmaceutical Biochemistry   (Switzerland)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

aggregation breaker; asymmetrical flow field flow fractionation; corticosteroids; molecular modelling; monoclonal antibody

Indexed keywords

BETAMETHASONE SODIUM PHOSPHATE; BEVACIZUMAB; DEXAMETHASONE SODIUM PHOSPHATE; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; TRIAMCINOLONE ACETONIDE;

ARTICLE; ASYMMETRICAL FLOW FIELD FLOW FRACTIONATION; BINDING SITE; CHEMICAL PARAMETERS; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DEXAMETHASONE; FRACTIONATION, FIELD FLOW; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PROTEIN MULTIMERIZATION; STRESS, MECHANICAL; TEMPERATURE;

EID: 84876501111     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0955-6     Document Type: Article

References (30)

1. Aggarwal S. What's fueling the biotech engine? Nat Biotechnol. 2007;25(10):1097-104.
2. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability and formulation. J Pharm Sci. 2007;96(1):1-26.
3. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75.
4. Demeule B, Gurny R, Arvinte T. Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates. Eur J Pharm Biopharm. 2006;62(2):121-30.
5. Harris RJ, Shire SJ, Winter C. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Dev Res. 2004;61(3):137-54.
6. Wang W, Nema S, Teagarden D. Protein aggregation-pathways and influencing factors. Int J Pharm. 2010;390(2):89-99.
7. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A. 2009;106(29):11937-42.
8. Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci. 2008;97(8):2924-35.
9. Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals. 2010;38(1):150-7.
10. Szenczi A, Kardos J, Medgyesi GA, Zavodszky P. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution. Biologicals. 2006;34(1):5-14.
11. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2009;20(3):158-65.
12. Veurink M, Stella C, Tabatabay C, Pournaras CJ, Gurny R. Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: an in vitro stability assessment. Eur J Pharm Biopharm. 2011;78(2):271-7.
13. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27(2):133-40.
14. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235-42.
15. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, et al. The Protein Data Bank. Acta Crystallogr D: Biol Crystallogr. 2002;58:899-907.
16. Muller YA, Christinger HW, Keyt BA, de Vos AM. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure. 1997;5(10):1325-38.
17. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 2001;293(5532):1155-9.
18. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673-80.
19. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23(21):2947-8.
20. Laskowski RA, MacArthur MW, Moss DM, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst. 1993;26:283-91.
21. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997;18(15):2714-23.
22. Mahler HC, Printz M, Kopf R, Schuller R, Muller R. Behaviour of polysorbate 20 during dialysis, concentration and filtration using membrane separation techniques. J Pharm Sci. 2008;97(2):764-74.
23. Fraunhofer W, Winter G. The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. Eur J Pharm Biopharm. 2004;58(2):369-83.
24. Mahler HC, Fries W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98(9):290-2934.
25. Schneider HJ, Schiestel T, Zimmermann P. The incremental approach to noncovalent interactions: Coulomb and van der Waals effect in organic ion pairs. J Am Chem Soc. 1992;114(20):7698-703.
26. Tissot AC, Vuilleumier S, Fersht AR. Importance of two buried salt bridges in the stability and folding pathway of barnase. Biochemistry. 1996;35(21):6786-94.
27. Roberts CJ. Non-native protein aggregation kinetics. Biotechnol Bioeng. 2007;98(5):927-38.
28. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in non-native protein aggregation. Pharm Res. 2003;20(9):1325-36.
29. Philo JS, Arakawa T. Mechanisms of protein aggregation. Curr Pharm Biotechnol. 2009;10(4):348-51.
30. Cleland JL, Lam X, Kendrick B, Yang J, Yang T-H, Overcashier D, et al. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci. 2001;90(3):310-21.